Cargando…

Sex differences in progression of kidney disease in sickle cell disease

Detalles Bibliográficos
Autores principales:	Ataga, Kenneth I., Zhou, Qingning, Saraf, Santosh L., Hankins, Jane S., Ciccone, Emily J., Loehr, Laura R., Garrett, Melanie E., Ashley-Koch, Allison E., Cai, Jianwen, Telen, Marilyn J., Derebail, Vimal K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153522/ https://www.ncbi.nlm.nih.gov/pubmed/36546431 http://dx.doi.org/10.3324/haematol.2022.281677

Ejemplares similares

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2020)

The glomerulopathy of sickle cell disease
por: Ataga, Kenneth I, et al.
Publicado: (2014)

Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
por: Doss, Jennifer F., et al.
Publicado: (2016)

Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy
por: Garrett, Melanie E., et al.
Publicado: (2022)

Variation and impact of polygenic hematologic traits in monogenic sickle cell disease
por: Pincez, Thomas, et al.
Publicado: (2022)

Pyridoxamine: another vitamin for sickle cell disease?
por: Telen, Marilyn J.
Publicado: (2020)

Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations
por: Obadina, Mofiyin, et al.
Publicado: (2023)

Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts
por: Nouraie, Mehdi, et al.
Publicado: (2020)

Biomarkers and recent advances in the management and therapy of sickle cell disease
por: Telen, Marilyn J.
Publicado: (2015)

Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia
por: Ataga, Kenneth I., et al.
Publicado: (2016)

RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes
por: Bundy, Joseph L., et al.
Publicado: (2019)

Clonal hematopoiesis in sickle cell disease
por: Liggett, L. Alexander, et al.
Publicado: (2022)

Is sickle cell disease the same everywhere?
por: Hankins, Jane
Publicado: (2012)

Drug Therapies for the Management of Sickle Cell Disease
por: Rai, Parul, et al.
Publicado: (2020)

Using Machine Learning to Predict Early Onset Acute Organ Failure in Critically Ill Intensive Care Unit Patients With Sickle Cell Disease: Retrospective Study
por: Mohammed, Akram, et al.
Publicado: (2020)

The Genomic Analysis of Erythrocyte microRNA Expression in Sickle Cell Diseases
por: Chen, Shao-Yin, et al.
Publicado: (2008)

Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium
por: Masese, Rita V., et al.
Publicado: (2021)

Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
por: Saraf, Santosh L., et al.
Publicado: (2019)

Validation of a novel point of care testing device for sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2015)

Using machine learning to predict rapid decline of kidney function in sickle cell anemia
por: Güntürkün, Fatma, et al.
Publicado: (2021)

Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease
por: Abdulmalik, Osheiza, et al.
Publicado: (2017)

Editorial: Pathogenesis and management of glomerular diseases
por: Lionaki, Sophia, et al.
Publicado: (2022)

In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress
por: Anderson, Blair R., et al.
Publicado: (2015)

Correction: In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress
por: Anderson, Blair R., et al.
Publicado: (2015)

High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia
por: Lebensburger, Jeffrey D., et al.
Publicado: (2020)

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: M., TELEN, et al.
Publicado: (2022)

Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease
por: Ataga, Kenneth I., et al.
Publicado: (2012)

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe
por: Maitra, Poulami, et al.
Publicado: (2017)

A Genome-Wide Association Study of Total Bilirubin and Cholelithiasis Risk in Sickle Cell Anemia
por: Milton, Jacqueline N., et al.
Publicado: (2012)

COVID-19 Vaccination Status and Disease Burden in Patients with Sickle Cell Disease
por: Han, Jin, et al.
Publicado: (2022)

Use of multiple urinary biomarkers for the early detection of chronic kidney disease in sickle cell anemia
por: Castro-Sesquen, Yagahira E., et al.
Publicado: (2023)

End Stage Kidney Disease Outcomes in Children and Young Adults with Sickle Cell Disease in the United States Renal Data System
por: Zahr, Rima S., et al.
Publicado: (2023)

Academic Performance of Children With Sickle Cell Disease in the United States: A Meta-Analysis
por: Heitzer, Andrew M., et al.
Publicado: (2021)

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: Saraf, S., et al.
Publicado: (2022)

Time to rethink haemoglobin threshold guidelines in sickle cell disease
por: Ballas, Samir K., et al.
Publicado: (2021)

Web-Based Technology to Improve Disease Knowledge Among Adolescents With Sickle Cell Disease: Pilot Study
por: Saulsberry, Anjelica C, et al.
Publicado: (2020)

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
por: Telen, M, et al.
Publicado: (2022)

Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease
por: Srisuwananukorn, Andrew, et al.
Publicado: (2020)

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA
por: Smeltzer, Matthew P, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ju75na6clltl9s7r2o3di5i19u